GlassScriptPhysician profile
Neeraja J Boddu
NPI 1356554281
$1,671.80
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $651 · 2024: $540 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $293.60 | 2022-2025 | Mounjaro, Lyumjev, Jardiance |
| Corcept Therapeutics | $226.87 | 2023-2025 | Korlym |
| Novo Nordisk INC | $138.36 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $125.56 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $119.01 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.64 | 2022-2025 | Jardiance |
| Insulet Corporation | $98.13 | 2022-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $85.69 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $73.11 | 2023-2024 | Afrezza |
| Sequel Med Tech, LLC | $59.41 | 2025 | Twiist |
| Medtronic, INC. | $45.49 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $44.54 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $41.30 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ultragenyx Pharmaceutical INC. | $37.94 | 2022-2023 | Crysvita |
| Recordati_rare_diseases_inc. | $36.06 | 2024 | Signifor Lar, Isturisa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.52 | 2023-2024 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $32.46 | 2023-2024 | Synthroid |
| Cequr Corporation | $26.70 | 2023 | Cequr Simplicity |
| Vivus LLC | $22.12 | 2023 | Qsymia |
| Horizon Therapeutics Plc | $15.74 | 2023 | Tepezza |
| Rgh Enterprises LLC | $15.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraja Boddu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.